FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma

Journal of Cell Biology

Volumn 170, Issue 6, 2005, Pages 903-912

  Bois, Philippe R J ^a   Izeradjene, Kamel ^a   Houghton, Peter J ^a   Cleveland, John L ^a   Houghton, Janet A ^a   Grosveld, Gerard C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; TAMOXIFEN CITRATE; TRANSCRIPTION FACTOR FKHR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL FUSION; CELL LINE; CELL MATURATION; CONTROLLED STUDY; EMBRYO; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INDOLES; LUCIFERASES; MICE; MICE, INBRED NOD; MICE, SCID; MYOBLASTS; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL;

EID: 24944487608     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.200501040     Document Type: Article

References (38)

1. Accili, D., and K.C. Arden. 2004. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 117:421-426.
2. Anderson, J., T. Gordon, A. McManus, T. Mapp, S. Gould, A. Kelsey, H. Mc-Dowell, R. Pinkerton, J. Shipley, and K. Pritchard-Jones. 2001. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br. J. Cancer. 85:831-835.
3. Anderson, M.J., G.D. Shelton, W.K. Cavenee, and K.C. Arden. 2001. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc. Natl. Acad. Sci. USA. 98:1589-1594.
4. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore. J.G. Seidman, J.A. Smith, and K. Struhl. 2001. Current Protocols in Molecular Biology. John Wiley and Sons, Inc., Somerset, NJ. 1512 pp.
5. Barr, F.G. 2001. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 20:5736-5746.
6. Berger, J., J. Hauber, R. Hauber, R. Geiger, and B.R. Cullen. 1988. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene. 66:1-10.
7. Birkenkamp, K.U., and P.J. Coffer. 2003. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem. Soc. Trans. 31:292-297.
8. Bois, P.R., and G.C. Grosveld. 2003. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J. 22:1147-1157.
9. Bois, P.R., V.C. Brochard, A.V.A. Salin-Cantegrel, J.L. Cleveland, and G.C. Grosveld. 2005. FoxO1a-cGMP-dependent kinase-I interactions orchestrate myoblast fusion. Mol. Cell. Biol. 25:7645-7656.
10. Brunet, A., A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, and M.E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:857-868.
11. Burgering, B.M., and G.J. Kops. 2002. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27:352-360.
12. Coleman, M.L., and M.F. Olson. 2002. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ. 9:493-504.
13. Conway, S.J., D.J. Henderson, M.L. Kirby, R.H. Anderson, and A.J. Copp. 1997. Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse. Cardiovasc. Res. 36:163-173.
14. Dias, P., B. Chen, B. Dilday, H. Palmer, H. Hosoi, S. Singh, C. Wu, X. Li, J. Thompson, D. Parham, et al. 2000. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am. J. Pathol. 156:399-408.
15. Dijkers, P.F., R.H. Medema, C. Pals, L. Banerji, N.S. Thomas, E.W. Lam, B.M. Burgering, J.A. Raaijmakers, J.W. Lammers, L. Koenderman, and P.J. Coffer. 2000. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol. Cell. Biol. 20:9138-9148.
16. Epstein, J.A., P. Lam, L. Jepeal, R.L. Maas, and D.N. Shapiro. 1995. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J. Biol. Chem. 270:11719-11722.
17. Fernando, P., J.F. Kelly, K. Balazsi, R.S. Slack, and L.A. Megeney. 2002. Caspase 3 activity is required for skeletal muscle differentiation. Proc. Natl. Acad. Sci. USA. 99:11025-11030.
18. Fredericks, W.J., N. Galili, S. Mukhopadhyay, G. Rovera, J. Bennicelli, F.G. Barr, and F.J. Rauscher III. 1995. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15:1522-1535.
19. Furuyama, T., T. Nakazawa, I. Nakano, and N. Mori. 2000. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem. J. 349:629-634.
20. Gallo, R., M. Serafini, L. Castellani, G. Falcone, and S. Alema. 1999. Distinct effects of Rac1 on differentiation of primary avian myoblasts. Mol. Biol. Cell. 10:3137-3150.
21. Hall, A., and C.D. Nobes. 2000. Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355:965-970.
22. Hayashi, S., and A.P. McMahon. 2002. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244:305-318.
23. Houghton, P.J., P.J. Cheshire, J.D. Hallman II, L. Lutz, H.S. Friedman, M.K. Danks, and J.A. Houghton. 1995. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36:393-403.
24. Keller, C., M.S. Hansen, C.M. Coffin, and M.R. Capecchi. 2004. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev. 18:2608-2613.
25. Kops, G.J., R.H. Medema, J. Glassford, M.A. Essers, P.F. Dijkers, P.J. Coffer, E.W. Lam, and B.M. Burgering. 2002. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol. 22:2025-2036.
26. Lagutina, I., S.J. Conway, J. Sublett, and G.C. Grosveld. 2002. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol. Cell. Biol. 22:7204-7216.
27. Lam, P.Y., J.E. Sublett, A.D. Hollenbach, and M.F. Roussel. 1999. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol. Cell. Biol. 19:594-601.
28. Mahfoudi, A., E. Roulet, S. Dauvois, M.G. Parker, and W. Wahli. 1995. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad. Sci. USA. 92:4206-4210.
29. Matsuzaki, H., H. Daitoku, M. Hatta, K. Tanaka, and A. Fukamizu. 2003. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl. Acad. Sci. USA. 100:11285-11290.
30. Medema, R.H., G.J. Kops, J.L. Bos, and B.M. Burgering. 2000. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 404:782-787.
31. Nishiyama, T., I. Kii, and A. Kudo. 2004. Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion. J. Biol. Chem. 279:47331-47339.
32. Qu, G., H. Yan, and A.R. Strauch. 1997. Actin isoform utilization during differentiation and remodeling of BC3H1 myogenic cells. J. Cell. Biochem. 67:514-527.
33. Rando, T.A., and H.M. Blau. 1994. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J. Cell Biol. 125:1275-1287.
34. Sabourin, L.A., and M.A. Rudnicki. 2000. The molecular regulation of myogenesis. Clin. Genet. 57:16-25.
35. Seale, P., L.A. Sabourin, A. Girgis-Gabardo, A. Mansouri, P. Gruss, and M.A. Rudnicki. 2000. Pax7 is required for the specification of myogenic satellite cells. Cell. 102:777-786.
36. Taylor, A.C., L. Shu, M.K. Danks, C.A. Poquette, S. Shetty, M.J. Thayer, P.J. Houghton, and L.C. Harris. 2000. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol. 35:96-103.
37. Tran, H., A. Brunet, E.C. Griffith, and M.E. Greenberg. 2003. The many forks in FOXO's road. Sci. STKE. 2003:RE5.
38. Wan, X., and L.J. Helman. 2003. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II- overexpressing rhabdomyosarcomas cells. Oncogene. 22:8205-8211.